© Georg Thieme Verlag Stuttgart · New York
Fish Oil Supplementation Versus Gemfibrozil Treatment in Hyperlipidemic NIDDMA Randomized Crossover Study
23. April 2007 (online)
To compare the impact of dietary fish oil supplementation (FQ. 22 ml daily, containing 4.6 g of n-3 (omega-3) fatty acids, equalling 14.4 mmol) on carbohydrate and lipid metabolism with that of conventional lipostatic therapy (Gemfibrozil (G), 900 mg daily, equalling 3.6 mmol) on hyperlipidemic non-insulin dependent diabetes mellitus (NIDDM), 10 patients were selected for a randomized, short-time, cross-over study. Each patient was treated for a duration of 2 weeks, with an individual washout period of 8 weeks. Metabolic variables and intravenous glucose tolerances (1.2 mmol/kg body weight, t = 30 min) were determined on days 1 and 15 of each treatment period. Plasma lipid concentrations were identical at baseline, but were reduced more markedly following G as against FO exposure (% change vs. baseline: total cholesterol (chol), - 13* */-6* (G vs FO: p = 0.05); total triglycerides (TG), - 39* */-18* * (p < 0.05): APO B, - 17* */- 10* (N.S.); LDL-chol, - 15* */0 (p < 0.02); VLDL-chol, - 50* * */- 34* * * (N.S.); VLDL-TG, - 44* * */- 27* * (N.S.); (p vs. baseline: * < 0.05, * * < 0.01, * * * < 0.001). Total-HDL, HDL2, HDL3 and APO A were not influenced by either FO or G. Neither FO nor G induced a change in intravenous glucose tolerances or associated basal and incremental concentrations of insulin and C-peptide. We concluded, based on short-time applications, that (a) neither treatment affected the carbohydrate metabolism in patients with NIDDM, and (b) a greater hypolipidemic efficacy had to be assigned to Gemfibrozil than to fish oil. It would therefore appear that Gemfibrozil acts as a useful lipostatic pharmacologic compound, whilst fish oil could serve as a potential ingredient of a prudent cardio-protective diet which favours the low plasma triglyceride concentrations found in NIDDM patients.
Fish Oil - Gemfibrozil - Hyperlipidemia - Plasma Lipids - Glucose Tolerance - HbA1c - Non-Insulin Dependent Diabetes Mellitus